Credit provider Morses Club (LON: MCL) has recovered all of yesterday’s loss and risen 241.7% to 1.6025p. JO Hambro sold its shareholding of 8.8 million shares. It previously said it intended to vote for the proposed AIM cancelation.
Chris Akers has increased his stake in Asimilar (LON: ASLR) from 6.63% to 7.41%. The share price jumped by 26.7% to 2.85p.
Ncondezi Energy Ltd (LON: NCCL) says a transmission integration study for its solar and battery energy storage system project in Mozambique confirms it is viable to provide 300MW of power to the National grid and the wider region of Africa. This will be via a two phase approach with the first 100MW using existing infrastructure and the second phase requiring capital investment. The share price improved by 6.45% to 0.825p.
Customer engagement software provider Pelatro (LON: PTRO) shares are recovering after three days of decline following a profit warning. The share price is 8.33% higher at 6.5p, down from 12.25p prior to the announcement.
Applied Graphene Materials (LON: AGM) is continuing its discussions with potential buyers of its assets and it hopes to select a preferred party. Any deal requires shareholder approval and so it will not be completed until after the end of January. Cost savings mean that the company’s cash could last until the end of February. The share price declined by 14.4% to 6.25p.
Portable oxygen concentrator developer Belluscura (LON: BELL) has added to its distributors and commenced selling in the US. There were 1,226 units shipped during 2022 and there are orders for more than that yet to be shipped. The share price rose 9.09% to 40p.
Argentina-focused oil and gas company Echo Energy (LON: ECHO) says the 70%-owned Santa Cruz project produced 532,302 barrels of oil equivalent. Reactivation of older wells will increase production. The share price fell 8.89% to 0.1025p.
Shares in Empire Metals Ltd (LON: EEE) have fallen a further 7.79% to 1.775p after yesterday’s exploration announcement. Management says great progress has been made at Pitfield and Eclipse-Gindalbie in Western Australia. The initial phase of geochemical mapping is nearing completion.
Cancer therapies developer ValiRx (LON: VAL) has raised £1m through a placing at 11p a share and is seeking up to £500,000 more through a broker option. Every four shares come with a warrant exercisable at 14p. The cash will fund a new internal research facility. The share price dipped by 8.54% to 11.25p.
